RxDoctor Payments Data

Jeffrey Mazer, MD

Critical Care Medicine · Albuquerque, NMNPI 1598982910

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.1%), education and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Intuitive Surgical at 50.4% of the total. Reporting peaked in 2024 at $6,034 and has fallen 87.2% since, to $770 in 2025. Among critical care medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,963in general payments, 2019–2025

Across 281 payments — averaging $35.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • AstraZeneca$1K
  • GSK$936
  • Boehringer Ingelheim$379
  • Grifols USA, LLC$348
  • Mylan Specialty L.p.$294
  • plus $2K from 29 others

What the payments were for

  • Travel & lodging$1,70317%
  • Food & beverage$5,19052%
  • Education$3,07031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,963 in reported general payments places this provider in the 95th percentile of 32 critical care medicine providers in New Mexico.

See all critical care medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$168,919
Medicare patients
540
Services billed
2,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate56$791,340
Trelegy ElliptaFluticasone/Umeclidin/Vilanter371$314,566
XolairOmalizumab72$224,945
Spiriva RespimatTiotropium Bromide283$223,095
Breo ElliptaFluticasone/Vilanterol266$156,831
Breztri AerosphereBudesonide/Glycopyr/Formoterol137$126,872
Dupixent PenDupilumab31$112,866
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr138$81,301
Stiolto RespimatTiotropium Br/Olodaterol Hcl125$77,377
EliquisApixaban82$58,967
Arnuity ElliptaFluticasone Furoate183$55,939
NucalaMepolizumab12$41,610
Incruse ElliptaUmeclidinium Bromide79$40,972
SymbicortBudesonide/Formoterol Fumarate88$32,245
Fluticasone-SalmeterolFluticasone Propion/Salmeterol172$32,143

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$379$1,091,811464 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Nucala$936$691,2191,049 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,097$166,214242 claims
PfizerEliquis$15$58,96782 claims
Lilly USA, LLCMounjaro$28$26,11724 claims
Johnson & JohnsonXarelto$32$15,23511 claims
MerckDulera$37$12,02630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 32 critical care medicine providers in New Mexico.

Other critical care medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →